Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Terapia Tecar nei Pazienti con Radicolopatia Lombare: Uno Studio Randomizzato Controllato

11 novembre 2026 aggiornato da: Izmir City Hospital

Efficacia della Tecarterapia rispetto alla Fisioterapia Convenzionale e al Trattamento Fittizio in Pazienti con Radicolopatia Lombare: Uno Studio Randomizzato Controllato

Lumbar radiculopathy is a common cause of low back and leg pain, most frequently resulting from lumbar disc herniation and nerve root irritation. Conservative management, including physical therapy modalities and exercise therapy, is generally recommended as first-line treatment for patients without progressive neurological deficits. Tecar therapy (Transfer of Energy Capacitive and Resistive) is a non-invasive electrotherapeutic modality that delivers high-frequency electromagnetic energy to deep tissues and has been proposed to reduce pain, enhance microcirculation, and promote tissue recovery. However, evidence regarding its effectiveness in lumbar radiculopathy remains limited.

The aim of this randomized controlled trial is to evaluate the efficacy of Tecar therapy in patients with lumbar radiculopathy and to compare its clinical effects with conventional physical therapy and sham Tecar treatment.

A total of 90 participants with unilateral L5 and/or S1 radiculopathy will be randomized into three groups: (1) conventional physical therapy, (2) Tecar therapy combined with standard physical therapy, and (3) sham Tecar therapy combined with standard physical therapy. All participants will receive standardized postural education and a home exercise program.

The primary outcome will be radicular leg pain intensity measured by the Visual Analog Scale (VAS) at Week 2. Secondary outcomes will include low back pain intensity (VAS), functional disability (Oswestry Disability Index), neuropathic pain characteristics (PainDETECT questionnaire), lumbar mobility (Modified-Modified Schober Test), nerve root irritability (Straight Leg Raise test), rescue analgesic consumption, and exercise adherence. Outcomes will be assessed at baseline, post-treatment (week 2), and follow-up visits at weeks 6 and 12.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This assessor-blinded, randomized controlled trial will be conducted in the Department of Physical Medicine and Rehabilitation at İzmir City Hospital, a tertiary-level outpatient center. The study will be designed and reported according to CONSORT recommendations.

Participants aged 18-65 years with clinically diagnosed unilateral L5 and/or S1 radiculopathy and symptom duration between 6 weeks and 6 months will be eligible. Diagnosis will primarily be based on clinical findings consistent with radiculopathy, including dermatomal leg pain and supportive neurological examination findings, while lumbar MRI and/or EMG will be used as confirmatory evidence. After written informed consent is obtained, eligible participants will be randomly assigned in a 1:1:1 ratio to one of three groups using computer-generated randomization with concealed allocation.

Group 1 will receive conventional physical therapy consisting of hot pack, continuous ultrasound therapy, and transcutaneous electrical nerve stimulation (TENS). Group 2 will receive Tecar therapy in addition to standardized base therapy. Tecar treatment will include capacitive and resistive energy transfer applied to the lumbar paraspinal region and gluteal muscles. Group 3 will receive sham Tecar therapy using the same procedure as the active Tecar protocol but with zero energy output. All groups will additionally receive standardized postural education and a home exercise program.

Outcome assessments will be performed by an independent physiatrist blinded to group allocation at four time points: baseline, post-treatment (week 2), and follow-up visits at weeks 6 and 12. The primary outcome will be change in radicular leg pain intensity from baseline to Week 2, measured by the Visual Analog Scale (VAS). Secondary outcomes will include low back pain intensity (VAS), functional disability (Oswestry Disability Index), neuropathic pain features (PainDETECT questionnaire), lumbar mobility (Modified-Modified Schober Test), nerve root irritability assessed with the Straight Leg Raise test, rescue analgesic consumption, and exercise adherence.

The study aims to determine whether Tecar therapy provides additional clinical benefit over conventional physical therapy and to evaluate the effectiveness of Tecar therapy beyond placebo effects using a sham-controlled design.

Tipo di studio

Interventistico

Iscrizione (Stimato)

90

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Izmir, Turchia (Türkiye), 35000
        • Reclutamento
        • İzmir City Hospital
        • Contatto:
      • Izmir, Turchia (Türkiye)
        • Reclutamento
        • İzmir Cİty Hospital
        • Contatto:
          • Ertan Yilmaz, Medical Doctor, Specialist
          • Numero di telefono: +905318431901
          • Email: ertnyilmzz@gmail.com

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Adults aged 18-65 years
  • Clinical diagnosis of unilateral L5 and/or S1 lumbar radiculopathy
  • Symptom duration between 6 weeks and 6 months
  • Average radicular pain intensity ≥3 on the Visual Analog Scale (VAS) during the previous month
  • Availability of lumbar MRI and/or EMG performed within the previous 6 months
  • Willingness to participate and ability to provide written informed consent

Exclusion Criteria:

  • Bilateral lumbar radiculopathy
  • Lumbar spinal canal stenosis confirmed by imaging or suspected clinically (e.g., neurogenic claudication)
  • Lower limb muscle strength <4/5 according to the Medical Research Council (MRC) scale
  • Use of analgesic medications other than paracetamol during the study period
  • Physical therapy treatment for low back or radicular pain within the past 3 months
  • Contraindications to physical therapy modalities or Tecar therapy
  • Any previous lumbar spine surgery, or interventional spinal procedures within the last 6 months
  • Pregnancy, malignancy, or systemic neurological or rheumatologic disease
  • Advanced spinal or lower extremity deformities (e.g., scoliosis >20°, grade 3-4 spondylolisthesis, vertebral fracture, advanced coxarthrosis)
  • Inability to complete the intervention protocol or follow-up assessments

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Conventional Physical Therapy

Participants in this group will receive conventional physical therapy consisting of hot pack, continuous ultrasound therapy, and transcutaneous electrical nerve stimulation (TENS) applied to the lumbar region. Treatments will be administered five times per week for two weeks (10 sessions). Participants will also receive standardized postural education and a home exercise program.

Conventional physical therapy will include a combination of hot pack, continuous ultrasound therapy, and transcutaneous electrical nerve stimulation (TENS) applied to the lumbar region. Treatment sessions will be conducted five times per week for two weeks. Participants will also receive standardized postural education and a home exercise program.

Sperimentale: Tecar Therapy

Participants in this group will receive Tecar therapy in addition to standardized base physical therapy consisting of hot pack and TENS. Tecar therapy will be applied to the lumbar paraspinal region and gluteal muscles using capacitive and resistive modes with adjustable energy output. Sessions will be performed three times per week for two weeks. Participants will also receive standardized postural education and a home exercise program.

Tecar therapy (Transfer of Energy Capacitive and Resistive) will be applied using capacitive and resistive modes to the lumbar paraspinal region and gluteal muscles. Energy output will be adjusted to approximately 50-70% of the device capacity to achieve a comfortably warm sensation. Each session will last approximately 25 minutes and will be performed three times per week for two weeks. All applications will be delivered using a hypothermic electrode head.

Comparatore fittizio: Arm Title

Participants in this group will receive sham Tecar therapy in addition to standardized base physical therapy consisting of hot pack and TENS. The sham procedure will follow the same protocol as the active Tecar therapy, including identical electrode contact and treatment duration, but the device will be set to zero energy output, preventing any thermal or electrical effect. Participants will also receive standardized postural education and a home exercise program.

Sham Tecar therapy will be delivered using the same device, electrode head, treatment duration, and therapist contact as the active Tecar therapy protocol. However, the device will be set to zero intensity output, preventing the delivery of electromagnetic energy or heat. This procedure is designed to mimic the active intervention while providing no therapeutic effect.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Radicular Leg Pain Intensity (Visual Analog Scale, VAS)
Lasso di tempo: Baseline to Week 2

Change from baseline to Week 2 in average radicular leg pain over the previous 7 days, measured on a 10-cm VAS (0 = no pain, 10 = worst imaginable pain).

Baseline to Week 2

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Low Back Pain Intensity (VAS)
Lasso di tempo: Baseline, Week 2, Week 6, and Week 12

Average low back pain over the previous 7 days, measured on a 10-cm VAS.

Baseline, Week 2, Week 6, and Week 12
Radicular Leg Pain Intensity (VAS) at Follow-up
Lasso di tempo: Baseline, Week 6, and Week 12

Average radicular leg pain over the previous 7 days, measured on a 10-cm VAS.

Baseline, Week 6, and Week 12
Neuropathic Pain Characteristics (PainDETECT Questionnaire)
Lasso di tempo: Baseline, Week 2, Week 6, and Week 12

Neuropathic pain features will be assessed using the PainDETECT Questionnaire, a validated self-report instrument ranging from -1 to 38 points. Higher scores indicate a greater likelihood of neuropathic pain components.

Baseline, Week 2, Week 6, and Week 12
Functional Disability (Oswestry Disability Index)
Lasso di tempo: Baseline, Week 2, Week 6, and Week 12

ODI version 2.0, percentage score from 0 to 100; higher scores indicate greater disability.

Baseline, Week 2, Week 6, and Week 12
Lumbar Mobility (Modified-Modified Schober Test)
Lasso di tempo: Baseline, Week 2, Week 6, and Week 12

Lumbar spine mobility will be assessed using the Modified-Modified Schober Test. The distance between two skin marks placed over the lumbar spine will be measured during maximal forward flexion.

Baseline, Week 2, Week 6, and Week 12
Nerve Root Irritability (Straight Leg Raise Test)
Lasso di tempo: Baseline, Week 2, Week 6, and Week 12

The Straight Leg Raise (SLR) test will be used to assess nerve root irritability. The angle at which radicular pain is reproduced during passive leg elevation will be measured using a goniometer.

Baseline, Week 2, Week 6, and Week 12
Rescue Medication Consumption
Lasso di tempo: Weeks 1, 2, 6, and 12

Total paracetamol intake (mg/week).

Weeks 1, 2, 6, and 12
Exercise Adherence
Lasso di tempo: Weeks 1, 2, 6, and 12

Self-reported percentage of target home exercise sessions completed.

Weeks 1, 2, 6, and 12

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Treatment Credibility and Expectancy
Lasso di tempo: Baseline

Credibility/Expectancy Questionnaire, administered before the first treatment session.

Baseline
Perceived Treatment Allocation
Lasso di tempo: Week 2

Participant belief about the treatment received (active, control, or do not know), TECAR and sham groups only.

Week 2

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Ertan Yilmaz, MD, Izmir City Hospital

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

15 aprile 2026

Completamento primario (Stimato)

15 aprile 2028

Completamento dello studio (Stimato)

15 dicembre 2028

Date di iscrizione allo studio

Primo inviato

14 marzo 2026

Primo inviato che soddisfa i criteri di controllo qualità

14 marzo 2026

Primo Inserito (Effettivo)

18 marzo 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2024-KAEK-23

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be publicly shared due to institutional data protection policies and privacy regulations. Only aggregated data will be reported in scientific publications.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .